Literature DB >> 25994603

Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus.

Giuseppe Derosa1,2, Fabrizio Querci3, Ivano Franzetti4, Pietro Dario Ragonesi5, Angela D'Angelo1, Pamela Maffioli1,6.   

Abstract

The aim of this study was to evaluate the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. We enrolled 148 normocholesterolemic patients with mild-to-moderate hypertension and type 2 diabetes mellitus. Patients were treated with barnidipine, 20 mg day(-1), in combination with losartan, 100 mg day(-1), or with telmisartan+hydrochlorothiazide, 80/12.5 mg day(-1), for 6 months. We assessed blood pressure (BP) on a monthly basis; additionally, blood samples were collected to assess, at baseline and after 6 months, the following parameters: fasting plasma glucose; glycated hemoglobin; fasting plasma insulin; HOMA index; and some adipocytokines, such as adiponectin (ADN), resistin, leptin, visfatin and vaspin. Patients were also subjected to an euglycemic hyperinsulinemic clamp to assess the M value and glucose infusion rate to ascertain their insulin sensitivity. One hundred and forty-one patients completed the study. The BP was reduced in both groups, although the reduction was greater with barnidipine+losartan (P<0.001 vs. baseline and P<0.01 vs. telmisartan+hydrochlorothiazide). Barnidipine+losartan increased the M value and glucose infusion rate during the euglycemic hyperinsulinemic clamp (P<0.05 vs. baseline and vs. telmisartan+hydrochlorothiazide). With respect to the levels of adipocytokines, ADN was increased (P<0.05), and resistin and leptin were reduced from baseline with barnidipine+losartan (P<0.05 vs. baseline), but they were not reduced with telmisartan+hydrochlorothiazide. Visfatin and vaspin were reduced by barnidipine+losartan compared with baseline (P<0.05). The adipocytokine levels obtained with barnidipine+losartan were significantly better than those obtained with telmisartan+hydrochlorothiazide (P<0.05 for all parameters). In addition to providing a greater BP reduction, barnidipine+losartan improved the insulin sensitivity, as assessed by an euglycemic hyperinsulinemic clamp, and improved some of the adipocytokines related to insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25994603     DOI: 10.1038/hr.2015.57

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  32 in total

Review 1.  Use and abuse of HOMA modeling.

Authors:  Tara M Wallace; Jonathan C Levy; David R Matthews
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

2.  Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients.

Authors:  Giuseppe Derosa; Pamela Maffioli; Ilaria Ferrari; Ilaria Palumbo; Sabrina Randazzo; Elena Fogari; Angela D'Angelo; Arrigo F G Cicero
Journal:  Hypertens Res       Date:  2010-11-25       Impact factor: 3.872

Review 3.  Leptin, its receptor and obesity.

Authors:  A Misra; A Garg
Journal:  J Investig Med       Date:  1996-12       Impact factor: 2.895

4.  Molecular characteristics of serum visfatin and differential detection by immunoassays.

Authors:  Antje Körner; Antje Garten; Matthias Blüher; Roy Tauscher; Jürgen Kratzsch; Wieland Kiess
Journal:  J Clin Endocrinol Metab       Date:  2007-09-18       Impact factor: 5.958

5.  Long-term effect of antihypertensive drugs on the risk of new-onset atrial fibrillation: a longitudinal cohort study.

Authors:  Gwo-Ping Jong; Hung-Yi Chen; Shu-Yi Li; Yi-sheng Liou
Journal:  Hypertens Res       Date:  2014-06-26       Impact factor: 3.872

6.  Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States.

Authors:  Katharina Wolf-Maier; Richard S Cooper; José R Banegas; Simona Giampaoli; Hans-Werner Hense; Michel Joffres; Mika Kastarinen; Neil Poulter; Paola Primatesta; Fernando Rodríguez-Artalejo; Birgitta Stegmayr; Michael Thamm; Jaakko Tuomilehto; Diego Vanuzzo; Fenicia Vescio
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

Review 7.  The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets.

Authors:  Ulrike Muscha Steckelings; Franziska Rompe; Elena Kaschina; Thomas Unger
Journal:  Fundam Clin Pharmacol       Date:  2009-10-09       Impact factor: 2.748

8.  The glycosylation of hemoglobin: relevance to diabetes mellitus.

Authors:  H F Bunn; K H Gabbay; P M Gallop
Journal:  Science       Date:  1978-04-07       Impact factor: 47.728

9.  Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans.

Authors:  Mary Yannakoulia; Nikos Yiannakouris; Susann Blüher; Antonia-Leda Matalas; Dorothy Klimis-Zacas; Christos S Mantzoros
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

10.  2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood
Journal:  Eur Heart J       Date:  2013-06-14       Impact factor: 29.983

View more
  9 in total

1.  Metabolic approaches to antihypertensive treatment in diabetic patients.

Authors:  Arrigo F Cicero; Giuliano Tocci
Journal:  Hypertens Res       Date:  2015-10-01       Impact factor: 3.872

Review 2.  Blood pressure management in patients with type 2 diabetes mellitus.

Authors:  Hisashi Kai
Journal:  Hypertens Res       Date:  2017-04-27       Impact factor: 3.872

3.  Calcium Channel Blockers for the Clinical Management of Hypertension.

Authors:  Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-10-11

Review 4.  Thiazide Diuretic-Induced Change in Fasting Plasma Glucose: a Meta-analysis of Randomized Clinical Trials.

Authors:  Jill J Hall; Dean T Eurich; Danielle Nagy; Lisa Tjosvold; John-Michael Gamble
Journal:  J Gen Intern Med       Date:  2020-03-10       Impact factor: 5.128

5.  The angiotensin II receptor antagonist, losartan, enhances regulator of G protein signaling 2 mRNA expression in vascular smooth muscle cells of Wistar rats.

Authors:  Yaqiong Wu; Suguru Nakagawa; Hidenori Takahashi; Yukari Kawabata; Etsu Suzuki; Yoshio Uehara
Journal:  Hypertens Res       Date:  2016-01-14       Impact factor: 3.872

Review 6.  Blood pressure control in type 2 diabetic patients.

Authors:  Alon Grossman; Ehud Grossman
Journal:  Cardiovasc Diabetol       Date:  2017-01-06       Impact factor: 9.951

7.  Serum resistin as an independent marker of aortic stiffness in patients with coronary artery disease.

Authors:  Ji-Hung Wang; Chung-Jen Lee; Chiu-Fen Yang; Yu-Chih Chen; Bang-Gee Hsu
Journal:  PLoS One       Date:  2017-08-14       Impact factor: 3.240

8.  Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes.

Authors:  Giuseppe Derosa; Angela D'Angelo; Davide Romano; Pamela Maffioli
Journal:  Drug Des Devel Ther       Date:  2017-05-16       Impact factor: 4.162

9.  Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus.

Authors:  Giuseppe Derosa; Amedeo Mugellini; Rosa Maria Pesce; Angela D'Angelo; Pamela Maffioli
Journal:  BMC Cardiovasc Disord       Date:  2016-04-12       Impact factor: 2.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.